| Grant number: | 16/17204-6 |
| Support type: | Scholarships in Brazil - Scientific Initiation |
| Effective date (Start): | February 01, 2017 |
| Effective date (End): | January 31, 2018 |
| Field of knowledge: | Health Sciences - Medicine - Medical Clinics |
| Principal researcher: | Nelson Hamerschlak |
| Grantee: | Bruna Franco Massa |
| Home Institution: | Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE). Sociedade Beneficente Israelita Brasileira Albert Einstein (SBIBAE). São Paulo , SP, Brazil |
Abstract The haematopoietic cell transplantation (HCT) is the administration of hematopoietic progenitor cells to reconstitute the patient's bone marrow. Those cells, also called progenitors cells or stem cells, are mononuclear cells morphologically similar to mature lymphocyte, which has the ability to regenerate the three blood series: erythrocytes, leukocytes and platelets. These cells are abundant in bone marrow, but are rare in the peripheral blood. The HCT can be separated into two types: autologous and allogeneic. The autologous uses haematopoietic progenitors cells from the patient. The autologous transplantation has less morbidity and mortality than allogeneic, but its main limitation is the high incidence of relapse. The autologous stem cells transplantation is especially indicated for the treatment of neoplastic diseases which are sensitive to chemotherapy (CT) or radiotherapy (RT) increasing probability to achieve complete remission (CR) or the disease free survival´s (DFS) and overall survival. Currently, the main treated neoplastic diseases with autologous transplantation are: Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Acute Myeloid Leukemia (AML) and pediatric tumors, such as Neuroblastoma, Wilms Tumor and Sarcomas. The autologous transplantation also has been used at the treatment of a wide variety of autoimmune diseases. (AU) | |